To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Survival and Risk of Vascular Complications in Myelofibrosis: A Population-Based Study from the Swedish MPN Group
Department of Medicine, Kalmar County Hospital, Kalmar, Sweden; Faculty of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Division of Hematology, Department of Medicine, NU Hospital Group, Uddevalla, Sweden.
Department of Hematology, University Hospital Linköping, Linköping, Sweden.
Division of Hematology, Department of Medicine, NU Hospital Group, Uddevalla, Sweden.
Show others and affiliations
2022 (English)In: European Journal of Haematology, ISSN 0902-4441, E-ISSN 1600-0609, Vol. 109, no 4, p. 336-342Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To gain knowledge of underlying risk factors for vascular complications and their impact on life expectancy in myelofibrosis.

METHODS: From a cohort of 392 myelofibrosis patients registered in the Swedish MPN registry 58 patients with vascular complications during follow-up were identified. Patients with vascular complications were compared with both 1:1 matched controls and the entire myelofibrosis cohort to explore potential risk factors for vascular complications and their impact on survival.

RESULTS: Incidence of vascular complications was 2.8 events per 100 patient-years and the majority of complications were thrombotic. Patients with complications were significantly older and had lower hemoglobin when compared to the entire cohort. In the case-control analysis, no significant risk factor differences were observed. The major cause of death was vascular complications and median survival was significantly impaired in patients with vascular complications (48 months) compared to controls (92 months). Inferior survival in patients with vascular complications was found to be dependent on IPSS risk category in a Cox regression model.

CONCLUSIONS: Vascular complications have a considerable impact on survival in MF. At diagnosis, risk assessment by IPSS does not only predict survival but is also associated with the risk of vascular complications.

Place, publisher, year, edition, pages
Munksgaard Forlag, 2022. Vol. 109, no 4, p. 336-342
Keywords [en]
IPSS, JAK2V617F, Myelofibrosis, Myeloproliferative neoplasms, Survival, Vascular complications
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-99621DOI: 10.1111/ejh.13813ISI: 000815366500001PubMedID: 35696444Scopus ID: 2-s2.0-85132576366OAI: oai:DiVA.org:oru-99621DiVA, id: diva2:1670654
Available from: 2022-06-16 Created: 2022-06-16 Last updated: 2022-09-29Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Ahlstrand, Erik

Search in DiVA

By author/editor
Ahlstrand, Erik
By organisation
Örebro University HospitalSchool of Medical Sciences
In the same journal
European Journal of Haematology
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 72 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf